NCT01245608View on ClinicalTrials.gov

Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.

PHASE3CompletedINTERVENTIONAL
Enrollment

2,400

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2018

Study Completion Date

September 30, 2018

Conditions
Cardiovascular Diseases
Interventions
DRUG

Polypill

Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg

Trial Locations (1)

Unknown

Golestan Cohort Center, Gonbad

All Listed Sponsors
collaborator

Golestan University of Medical sciences

OTHER

collaborator

University of Birmingham

OTHER

lead

Tehran University of Medical Sciences

OTHER

NCT01245608 - Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables. | Biotech Hunter | Biotech Hunter